Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Anakinra (Primary)
- Indications Fever; Mucositis
- Focus Adverse reactions
- Acronyms AFFECT-1
- 31 Oct 2017 Last checked against ClinicalTrials.gov record
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 New trial record